MARK PEQUIGNOT: Open Payments
NPI 1770272148 · ROSEBURG, OR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$380 in 21 payments from 11 companies in 2025. Trend: 2023 $137 · 2024 $330 · 2025 $380
Food & beverage: $380
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 7 | $126 |
| Exact Sciences Corporation | 2 | $44 |
| ABBVIE INC. | 2 | $40 |
| Sumitomo Pharma America, Inc. | 2 | $35 |
| Lilly USA, LLC | 2 | $32 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $21 |
| Astellas Pharma US Inc | 1 | $19 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
Products named: Ozempic, Wegovy, The Cologuard Plus Collection Kit, QULIPTA, GEMTESA, MOUNJARO, REXULTI, Kerendia.
Industry payments across OR — which companies pay providers there.
